Unique ID issued by UMIN | UMIN000013727 |
---|---|
Receipt number | R000016028 |
Scientific Title | Efficacy of Tolvaptan in acute heart failure patients with preserved left ventricular ejection fraction |
Date of disclosure of the study information | 2014/04/16 |
Last modified on | 2018/04/19 09:22:16 |
Efficacy of Tolvaptan in acute heart failure patients with preserved left ventricular ejection fraction
Efficacy of Tolvaptan in acute heart failure patients with preserved left ventricular ejection fraction
Efficacy of Tolvaptan in acute heart failure patients with preserved left ventricular ejection fraction
Efficacy of Tolvaptan in acute heart failure patients with preserved left ventricular ejection fraction
Japan |
acute decompensated heart failure
Cardiology |
Others
NO
To elucidate the efficacy of Tolvaptan in acute heart failure patients with preserved left ventricular ejection fraction using cardiac sympathetic nerve activity as an indicator
Safety,Efficacy
H/M MIBG uptake ratio on the delayed images,
Changes in washout rate of cardiac MIBG
1)blood biomarkers: vasopressin, three fractions of catecholamine, renin activity, aldosterone levels and serum osmolality
2)urinary biomarker: urinary albumin, urine beta2-microglobulin, urinary L-FABP and urine osmolality
3) Transthoracic echocardiography: LVEF, LVDd/Ds, E/e', LAD
4) Holter electrocardiogram: (TWA, HRV, HRT)
5) arrhythmia
6) cardiovascular event
7) acute kidney injury
Interventional
Parallel
Randomized
Individual
Open -but assessor(s) are blinded
Active
2
Treatment
Medicine |
Conventional therapy group
Tolvaptan add-on therapy group
20 | years-old | <= |
90 | years-old | > |
Male and Female
1) Patients with left ventricular ejection fraction>=45%
2) Patients with at least one sign of congestion (edema, pulmonary congestion, pleural effusion, jugular venous distention, orthopnea)
3)Patients who received sufficient explanation, understood it and gave written consent based on their free will, before participating in this study
1) Patients with hypernatremia (Na>147mEq/L)
2) Patients who do not need diuretic therapy because of dehydration
3) Patients with cardiovascular shock
4) Patients with anuria or patients under hemodialysis
5) Patients with acute coronary syndrome
6) Patients with insensitivity to thirst or difficulty in water intake
7) Patients who need mechanical circulatory assist device (IABP・PCPS)
8) Patients with malignant tumor
9) Patients who need temporary pacing because of bradycardia
10) Patients who were judged inappropriate by the principal investigator
120
1st name | |
Middle name | |
Last name | Shunsuke Tamaki |
Osaka General Medical Center
Department of Cardiology
3-1-56 Bandai-Higashi, Sumiyoshi-ku, Osaka
06-6692-1201
kenkyusien@gh.opho.jp
1st name | |
Middle name | |
Last name | Shunsuke Tamaki |
Osaka General Medical Center
Department of Cardiology
3-1-56 Bandai-Higashi, Sumiyoshi-ku, Osaka
06-6692-1201
kenkyusien@gh.opho.jp
Osaka General Medical Center
None
Self funding
NO
2014 | Year | 04 | Month | 16 | Day |
Unpublished
Completed
2014 | Year | 02 | Month | 16 | Day |
2014 | Year | 04 | Month | 01 | Day |
2017 | Year | 12 | Month | 31 | Day |
2014 | Year | 04 | Month | 16 | Day |
2018 | Year | 04 | Month | 19 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000016028
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |